相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The MANIFEST IO prospective study has recruited its first patient, marking a major milestone for the UK-wide platform launched in Q4 2024. - The study aims to recruit 3,000 patients across the UK starting immunotherapy for breast, bladder, kidney cancer, and melanoma. - Researchers will perform deep clinical and biological profiling to understand why some patients benefit more from immunotherapy and why toxicities occur. - The platform seeks to discover predictive biomarkers and new therapeutic targets to enable more precise, effective, and better-tolerated immunotherapies.
- Outrun Therapeutics has selected a first-in-class E6AP ubiquitin ligase inhibitor as its lead programme for treating HPV-positive head and neck cancer, with clinical entry expected in 2027. - The novel therapeutic strategy aims to stabilize tumor suppressor proteins by inhibiting E6AP, targeting an underserved patient population representing 4.5% of cancers worldwide. - The company has assembled a world-class Scientific Advisory Board including renowned experts in E3 ligase biology and head and neck cancer to guide clinical development. - The programme has demonstrated strong preclinical proof of mechanism both in vitro and in vivo, positioning it as a potential breakthrough treatment for this challenging indication.
- The groundbreaking LION trial investigates the combination of celecoxib with immunotherapy to treat advanced triple-negative breast cancer, non-small cell lung cancer, and renal cell carcinoma. - Led by The Christie NHS Foundation Trust, the trial aims to recruit 89 patients across six UK sites, with 11 patients already enrolled in this innovative treatment approach. - The study, funded by The Christie Charity and The Jon Moulton Charity Trust, explores whether reducing inflammation can enhance immunotherapy's effectiveness in fighting cancer.
